Key Insights

Highlights

Success Rate

82% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.5%

2 terminated out of 21 trials

Success Rate

81.8%

-4.7% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed with results

Key Signals

1 with results82% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (4)
P 1 (4)
P 2 (5)
P 3 (1)

Trial Status

Completed9
Unknown4
Active Not Recruiting2
Terminated2
Recruiting2
Not Yet Recruiting1

Trial Success Rate

81.8%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT04482894Not ApplicableActive Not RecruitingPrimary

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

NCT07296445Phase 3Not Yet Recruiting

A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)

NCT05823571Phase 1Active Not RecruitingPrimary

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

NCT03680677RecruitingPrimary

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

NCT05236296Not ApplicableCompletedPrimary

Emotion and Symptom-focused Engagement for Caregivers (EASE-CG) Pilot Study

NCT07046481Not ApplicableWithdrawnPrimary

Physical Activity and Quality of Life in Childhood Cancersurvivors- a Long-term Follow-up

NCT06335277Recruiting

Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology

NCT04051216Not ApplicableCompletedPrimary

The SMART CART Study: Health Information Technology

NCT05969600CompletedPrimary

The Relapses in Childhood Acute Lymphoplastic Leukemia Excluding L3

NCT03434704Phase 2Completed

Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole

NCT03564470Phase 2Unknown

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

NCT04710212Completed

Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies

NCT03297476CompletedPrimary

Clinical Application of Novel Panels for Early Precision Diagnosis and Relapse Prediction in High-risk Leukemia

NCT04194086Phase 1CompletedPrimary

Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia

NCT04745416CompletedPrimary

Clinical Characteristics of Patients With Leukemia and COVID-19

NCT04236063Completed

Rehabilitation Needs of the Malaysian Haematological Cancer Survivors

NCT03963024Phase 1Terminated

Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT

NCT03336632Phase 2UnknownPrimary

Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT

NCT01050764Phase 1TerminatedPrimary

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

NCT03564704Phase 2Unknown

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Scroll to load more

Research Network

Activity Timeline